Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

INTRODUCTION. Our understanding of the biologic heterogeneity of endometrial cancer has improved, but which patients benefit from single-agent versus combination immune checkpoint blockade remains unclear. METHODS. We conducted a single-center, randomized, open-label, phase 2 study of durvalumab 150...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinstein, Maria M., Doria, Eric Rios, Konner, Jason, Lichtman, Stuart, Zhou, Qin, Iasonos, Alexia, Sarasohn, Debra, Troso-Sandoval, Tiffany, Friedman, Claire, O'Cearbhaill, Roisin, Cadoo, Karen, Kyi, Chrisann, Cohen, Seth, Soldan, Krysten, Billinson, Eric, Caird, Imogen, Jang, Dasom, Eid, Khalil, Shah, Pooja, Guillen, Joyce, Aghajanian, Carol, Zamarin, Dmitriy, Makker, Vicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925401/
https://www.ncbi.nlm.nih.gov/pubmed/36512912
http://dx.doi.org/10.1016/j.ygyno.2022.11.028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925401/
https://www.ncbi.nlm.nih.gov/pubmed/36512912
http://dx.doi.org/10.1016/j.ygyno.2022.11.028

Ejemplares similares